Theralase Technologies Stock Total Asset
| TLT Stock | CAD 0.16 0.01 6.67% |
Fundamental analysis of Theralase Technologies allows traders to better anticipate movements in Theralase Technologies' stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year | ||
| Total Assets | 3.2 M | 4.4 M |
Theralase | Total Asset |
Theralase Technologies Company Total Asset Analysis
Theralase Technologies' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Theralase Technologies Total Asset | 3.25 M |
Most of Theralase Technologies' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Theralase Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Theralase Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Theralase Technologies is extremely important. It helps to project a fair market value of Theralase Stock properly, considering its historical fundamentals such as Total Asset. Since Theralase Technologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Theralase Technologies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Theralase Technologies' interrelated accounts and indicators.
Click cells to compare fundamentals
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Theralase Total Assets
Total Assets |
|
Based on the latest financial disclosure, Theralase Technologies has a Total Asset of 3.25 M. This is 99.96% lower than that of the Health Care Equipment & Supplies sector and 99.95% lower than that of the Health Care industry. The total asset for all Canada stocks is 99.99% higher than that of the company.
Theralase Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Theralase Technologies' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Theralase Technologies could also be used in its relative valuation, which is a method of valuing Theralase Technologies by comparing valuation metrics of similar companies.Theralase Technologies is currently under evaluation in total asset category among its peers.
Theralase Technologies Current Valuation Drivers
We derive many important indicators used in calculating different scores of Theralase Technologies from analyzing Theralase Technologies' financial statements. These drivers represent accounts that assess Theralase Technologies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Theralase Technologies' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 38.8M | 77.6M | 66.5M | 39.6M | 63.6M | 66.8M | |
| Enterprise Value | 31.0M | 74.0M | 65.5M | 39.9M | 63.6M | 66.8M |
Theralase Fundamentals
| Return On Equity | -2.69 | ||||
| Return On Asset | -0.88 | ||||
| Operating Margin | (3.65) % | ||||
| Current Valuation | 41.37 M | ||||
| Shares Outstanding | 257.06 M | ||||
| Shares Owned By Insiders | 8.23 % | ||||
| Number Of Shares Shorted | 1.03 M | ||||
| Price To Earning | (9.79) X | ||||
| Price To Book | 37.64 X | ||||
| Price To Sales | 39.80 X | ||||
| Revenue | 1.03 M | ||||
| Gross Profit | 554.01 K | ||||
| EBITDA | (4.24 M) | ||||
| Net Income | (4.26 M) | ||||
| Cash And Equivalents | 1.67 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 1.18 M | ||||
| Current Ratio | 3.45 X | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (3.33 M) | ||||
| Short Ratio | 4.37 X | ||||
| Earnings Per Share | (0.02) X | ||||
| Target Price | 0.7 | ||||
| Beta | 0.55 | ||||
| Market Capitalization | 39.84 M | ||||
| Total Asset | 3.25 M | ||||
| Retained Earnings | (67.5 M) | ||||
| Working Capital | 597.72 K | ||||
| Net Asset | 3.25 M |
About Theralase Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Theralase Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theralase Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theralase Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Theralase Stock Analysis
When running Theralase Technologies' price analysis, check to measure Theralase Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theralase Technologies is operating at the current time. Most of Theralase Technologies' value examination focuses on studying past and present price action to predict the probability of Theralase Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theralase Technologies' price. Additionally, you may evaluate how the addition of Theralase Technologies to your portfolios can decrease your overall portfolio volatility.